Latest News
-
Tuesday - April 20, 2021
RAGT and Bayer sign an agreement to develop hybrid wheat seeds for European markets
New partnership aims to provide farmers with new high-potential wheat varieties, enhancing sustainable agricultural practices » more
-
Wednesday - April 14, 2021
Apply now for THRIVE | Bayer sustainability challenge
Bayer and SVG Ventures | THRIVE partner to tackle agriculture’s grand challenge » more
-
Saturday - April 10, 2021
Not intended for U.S. and UK Media – Plenary Session at AACR Annual Meeting 2021:
Combination of copanlisib and rituximab significantly increases progression-free survival in patients with relapsed indolent non-Hodgkin's Lymphoma
Copanlisib is the first and only PI3K inhibitor to demonstrate broad and superior efficacy in combination with rituximab in patients with relapsed indolent non-Hodgkin’s Lymphoma (iNHL) compared to rituximab and placebo / Phase III trial CHRONOS-3 showed the combination of copanlisib and rituximab resulted in a 48% reduction in the risk of disease progression or death in patients with iNHL / The strong reduction in risk of progression or death was observed across all prespecified iNHL subtypes / The adverse event (AE) profile of the copanlisib and rituximab combination was manageable and generally consistent with previous data on copanlisib and rituximab as individual therapies / Bayer is discussing the data from CHRONOS-3 with health authorities worldwide » more
-
Tuesday - April 6, 2021
Not intended for U.S. and UK Media
Bayer to present new clinical data in indolent non-Hodgkin’s Lymphoma and additional research on its oncology portfolio at AACR Annual Meeting 2021
Oral presentation in a Clinical Trials Plenary Session on April 10 to highlight the Phase III trial CHRONOS-3 evaluating copanlisib (Aliqopa™) plus rituximab compared to rituximab and placebo in relapsed indolent non-Hodgkin’s Lymphoma (iNHL) / New data also include research into Bayer’s precision oncology treatment larotrectinib (Vitrakvi™) on long-term outcomes in patients with TRK fusion cancer and biomarker research in this patient population / Data from Bayer’s established and growing prostate cancer portfolio, including darolutamide (Nubeqa™), radium-223 dichloride (Xofigo™), and targeted thorium conjugates (TTC) from its Targeted Alpha Therapy platform will be showcased / Introduction of novel treatment approaches in the areas of precision molecular oncology and immuno-oncology » more
-
Wednesday - March 31, 2021
Industry leading digital farming platform Climate FieldView™ launches in South Africa
The Climate Corporation, Bayer’s digital agriculture arm, expands its global footprint to advance data-driven innovation for farmers around the world » more
-
Tuesday - March 23, 2021
Not intended for U.S. and UK Media
Bayer receives approval for Vitrakvi™ in Japan
Precision oncology treatment Vitrakvi™ (larotrectinib) approved for the treatment of NTRK fusion-positive advanced or recurrent solid tumors / In clinical studies, larotrectinib demonstrated high response rates and durable responses in adults and children with TRK fusion cancer, including responses and a high disease control rate in primary central nervous system (CNS) tumors / The Japanese marketing authorization of Vitrakvi follows the approval of the expanded use of FoundationOne®CDx, a comprehensive genomic profiling (CGP) test, in Japan for use as a companion diagnostic (CDx) to identify patients with TRK fusion cancer who could benefit from treatment with Vitrakvi » more
-
Friday - March 12, 2021
Bayer’s unmatched R&D investment powers industry-leading Crop Science portfolio
Commercialized ten new formulations and more than 430 new hybrids and varieties across corn, soybeans, cotton and vegetables. Three biotech trait projects advance to launch phase / Advanced eight new small molecule crop protection actives / Leading soybean pipeline to offer the greatest weed control flexibility, premium genetics » more
-
Friday - March 12, 2021
Elections at the Annual Stockholders' Meeting on April 27, 2021:
Bayer to further strengthen expertise and international profile of its Supervisory Board
Fei-Fei Li and Alberto Weisser proposed as successors to Johanna Faber and Prof. Dr. Wolfgang Plischke / Supervisory Board compensation to be adjusted » more
-
Wednesday - March 10, 2021
Capital Markets Day 2021:
Bayer expects dynamic growth with higher profitability in the coming years and is accelerating its transformation
Crop Science: Clear innovation leader in its industry – expected sales and earnings growth above market / Pharmaceuticals: Further growth planned through 2023, new products expected to largely offset the effect of patent expirations – position in cell and gene therapy to be expanded / Consumer Health: Moved from industry underperformer to outperformer – further sales and earnings improvements planned / Core earnings per share anticipated to increase to 7.00 to 7.50 euros by 2024 / Further operational improvements to raise free cash flow to 5 billion euros by 2024 / Bayer in an excellent position to benefit from the biorevolution in health and nutrition » more
-
Monday - March 1, 2021
International conference for horticulturists marks debut of Bayer’s latest crop protection product
Bayer to launch Vynyty Citrus®, its newest biological product to control citrus farm pests during virtual symposium » more
-
Thursday - February 25, 2021
Financial News Conference
Full Year 2020 Results » more
-
Thursday - February 25, 2021
Fiscal 2020:
Bayer delivers robust performance despite pandemic – foundation laid for future growth
Group sales at 41.400 billion euros, impacted by negative currency effects of 1.941 billion euros (Fx & portfolio adj. plus 0.6 percent) / EBITDA before special items level with prior year at 11.461 billion euros (minus 0.1 percent) – currency effects offset by stringent cost management / Crop Science and Pharmaceuticals report stable operational business, Consumer Health sees strong growth / Core earnings per share at 6.39 euros (plus 0.2 percent) / Earnings per share at minus 10.68 euros (2019: plus 4.17 euros), impacted by litigation provisions and impairments / Net financial debt improves by 11.8 percent to 30.041 billion euros / Proposed dividend of 2.00 euros per share (2019: 2.80 euros) / Portfolio and innovation capabilities strengthened / Outlook for 2021: positive momentum and solid operational growth – stable earnings at constant currencies » more
-
Wednesday - February 24, 2021
Bayer to Divest Environmental Science Professional Business and Further Strengthen Leadership Team of Crop Science Division » more
-
Monday - February 22, 2021
Bayer strives for gender parity in all management levels by 2030, advances overall inclusion and diversity approach » more
-
Wednesday - February 17, 2021
Prestigious Award from the Bayer Foundation:
Otto Bayer Award goes to Prof. Ruth Ley PhD
Director of the Department of Microbiome Research at the Max Planck Institute for Developmental Biology in Tübingen is honored for outstanding achievements in her field / Four young scientists receive the Bayer Early Excellence in Science Award / Werner Baumann: “The Bio Revolution has the potential to transform our economies and contribute to overcoming global challenges.” » more
-
Monday - February 15, 2021
Bayer Future of Farming Dialogue:
Bayer Fueling Growth Opportunities for Sustainable Agriculture Through Collaborative Innovation Model
Unique Open Innovation model, alongside Leaps by Bayer impact investments, drive future agricultural advancements in gene editing, plant health and improved food quality / Leveraging the latest agricultural technologies in new ways to reduce environmental impact and solve big challenges in food and agriculture » more
-
Monday - February 15, 2021
Bayer Wuppertal:
North Rhine-Westphalia’s State Premier Armin Laschet visits future Bayer AG vaccine production site » more
-
Tuesday - February 9, 2021
Not intended for U.S. and UK Media
Bayer submits finerenone for marketing authorization in China for the treatment of chronic kidney disease in type 2 diabetes » more
-
Monday - February 8, 2021
Not intended for U.S. and UK Media
New data presented at 2021 ASCO GU Cancers Symposium add to robustness of the overall survival benefit and favorable safety profile for Nubeqa™
New analyses from the Phase III ARAMIS trial further strengthen the overall survival benefit and favorable safety profile of darolutamide (Nubeqa™) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Additional data from darolutamide and radium-223 dichloride (Xofigo™) trials demonstrate Bayer’s continued commitment to ongoing prostate cancer research to bring meaningful benefit to the lives of men across different stages of the disease / Expert-led and patient perspectives as well as additional prostate cancer educational resources for media can be found on Bayer’s ASCO GU Virtual Media Hub » more
-
Monday - February 8, 2021
Not intended for U.S. and UK Media
Bayer and Orion expand development program for darolutamide in prostate cancer
Phase III study ARANOTE to be initiated in metastatic hormone-sensitive prostate cancer (mHSPC) assessing the novel androgen-receptor antagonist in combination with standard androgen deprivation therapy / Start of patient enrollment expected by the end of Q1 2021 / Study adds to the robust development program for NUBEQA, exploring an opportunity to help even more patients with prostate cancer » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Tuesday, April 27, 2021
Annual Stockholders' Meeting 2021
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV